| Previous close | 29.20 |
| Open | 29.20 |
| Bid | 43.10 |
| Ask | 47.50 |
| Strike | 75.00 |
| Expiry date | 2024-05-17 |
| Day's range | 29.20 - 29.20 |
| Contract range | N/A |
| Volume | |
| Open interest | 1 |
ZacksSarepta (SRPT) Q1 Earnings Beat Estimates, Revenues Up Y/Y
Sarepta (SRPT) reports better-than-expected Q1 earnings on the back of strong sales for recently-approved DMD gene therapy Elevidys.
Insider MonkeySarepta Therapeutics, Inc. (NASDAQ:SRPT) Q1 2024 Earnings Call Transcript
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Q1 2024 Earnings Call Transcript May 1, 2024 Sarepta Therapeutics, Inc. beats earnings expectations. Reported EPS is $0.37, expectations were $-0.11. Sarepta Therapeutics, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good afternoon and welcome […]
- Thomson Reuters StreetEvents
Q1 2024 Sarepta Therapeutics Inc Earnings Call
Q1 2024 Sarepta Therapeutics Inc Earnings Call
© 2024 Yahoo. All rights reserved.